Inhibition of the Osteoclast Activity with the Application of Recombinant Murine RANK Protein

REFERENCES

• Simonet, W.S., Lacey, D.L., Dunstan, C.R., . (1997). Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309–319.
   PubMed Web of Science ®Google Scholar
• Anderson, M.A., Maraskovasky, E., Billingsley, W.L., . (1997). A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175–179.
   PubMed Web of Science ®Google Scholar
• Udagawa, N., Takahashi, N., Matsuzaki, K., . (1998). Osteoblasts/stromal cells activate osteoclase function through osteoclast different ion factor (ODF). Second Joint Meeting of the ASBMR and the IBMS, San Francisco, CA, 1998.
   Google Scholar
• Miller, Robert E., Branstetter, Daniel, Armstrong, Allison, . (2007). Receptor activator of NF-B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. The Journal of Immunology 179: 266–274.
   PubMed Web of Science ®Google Scholar
• Sordillo, E.M., Pearse, R.N. RANK-Fc: A therapeutic antagonist for RANK-L in myeloma. American Cancer Society 97 (3): 802–812.
   Google Scholar
• Wang, Bao-Li, Liang, Hui, Zheng, Fang, Li, Xiao-Xia, . (2007). Recombinant soluble receptor activator of nuclear factor-κB inhibits parathyroid hormone-induced osteoclastogenesis in vitro. Acta Physiologica Sinica 59 2: 169–174.
   PubMedGoogle Scholar
• Feeley, B.T., Liu, N.Q., Conduah, A.H., . (2007). Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and rank: Fc administration. J Bone Miner Res. 22 (3): 486.
   Web of Science ®Google Scholar
• Hsu, H., Lacey D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H-L., Elliot, G., Kelley, M. J., Sarosi, I., Wang, L., Xia, X-Z., Elliot, R., Chiu, L., Black, T., Scully, S., Capparelli, C., Morony, S., Shimamoto, G., Bass, M. B., Boyle, W. J. (1999). Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96: 3540–3545.
   PubMed Web of Science ®Google Scholar
• Nakagawa, N., Kinosaki, M., Yamaguchi, K., . (1998). RANK Is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochemical and Biophysical Research Communications 253, 395–400.
   PubMed Web of Science ®Google Scholar
• Babatunde, O., Anderson, D.M., Traianedes, K. . (2001). Therapeutic efficacy of a soluble receptor activator of nuclear factor kB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Research 61: 2572–2578.
   PubMed Web of Science ®Google Scholar
• Shipman, C.M., Croucher, P.I., . (2003). Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 63: 912–916.
   PubMed Web of Science ®Google Scholar
• Holen, I., Croucher, P.I., Hamdy, F.C., Eaton, C.L., . (2002). Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 62: 1619–1623.
   PubMed Web of Science ®Google Scholar
• Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Siverman, C., Dul, E., Appelbaum, E. R., Eichman, C., Diprinzo, R., Dodds, R. A., James, I. E., Rosenberg, M., Lee, J. C., Young, P. R. (1998). Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem 273: 14363–14367.
   PubMed Web of Science ®Google Scholar
• Zhang, J., Dai, J., Yao, Z., Lu, Y., Dougall, W., Keller, E.T. (2003). Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 63: 7883–7890.
   PubMed Web of Science ®Google Scholar
• Li, J., Sarosi, I., Yan, X-Q., Morony, S., Capparelli, C., Tan, H-L., McCabe, S., Elliott, R., Scully, S., Van, G., Kaufman, S., Juan, S-C., Sun, Y., Tarpley, J., Martin, L., Christensen, K., McCabe, J., Kostenuik, P., Hsu, H., Fletcher, F., Dunstan, C. R., Lacey, D. L., Boyle, W. J. (2000). RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97: 1566–1571.
   PubMed Web of Science ®Google Scholar
• Bagi, C.M., Ammann, P., Rizzoli, R., . (1997). Effect of estrogen deficiency on cancellous and cortical bone structure and strength of the femoral neck in rats. Calcif Tissue Int. 61: 336–344.
   PubMed Web of Science ®Google Scholar
• Cheng, X., Kinosaki, M., Takami, M., . (2004). Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo[J]. J Biol Chem 279 (9): 8269–8277.
   PubMed Web of Science ®Google Scholar